ClinicalTrials.gg
RecruitingNCT05969548Updated Apr 4, 2025

pBFS-guided cTBS at Different Doses for Aphasia After Stroke

An interventional study of active 1200-pulse continuous Theta Burst Stimulation and active 2400-pulse continuous Theta Burst Stimulation in Stroke and Aphasia, sponsored by Changping Laboratory. Recruiting at 2 sites in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Changping Laboratory · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
319th of 432
60 · median 169
Started
2023
with 61 others
No phase
264 of 613
123 open now
Primary completion
2025-09
later than 58 of 262 live
Registered
354th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 319th largest by planned enrollment of the 432 interventional ones that give a count, is one of 62 that started in 2023, is one of 264 with no phase, reaches primary completion later than 58 of the 262 other live ones, and was the 354th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

The objective of this trial is to evaluate the effectiveness and safeness of different doses of continuous Theta Burst Stimulation (cTBS) over the right Superior Frontal Gyrus (SFG), guided by personalized Brain Function Sector (pBFS) technology, on language function recovery in patients with post-stroke aphasia.

Read the detailed description

Increasing evidence suggests that rTMS has been effective in treating various psychological and neurological diseases, including treating post-stroke symptoms. Using the personalized brain functional sectors (pBFS) technique, investigators could precisely identify individualized brain functional networks and the personalized language-related stimulation site based on the resting-state functional MRI data. The current study proposes to conduct a double-blinded, randomized and parallel controlled design trial, to investigate the efficacy and safety of pBFS-guided personalized rTMS intervention in post-stroke aphasic patients.

Subjects will be randomly assigned to the following six groups: active 1200-pulse cTBS group, active 2400-pulse cTBS group, active 3600-pulse cTBS group, sham 1200-pulse cTBS group, sham 2400-pulse cTBS group, or sham 3600-pulse cTBS group. The allocation ratio will be 3:3:3:1:1:1. The stimulation protocol consisted of a 3-week treatment, with 5 consecutive workdays each week (totally 15 day-treatment). The stimulation procedure will be assisted with real-time neuronavigation to ensure its precision.

03

Conditions studied

  • Stroke
  • Aphasia

Browse trials for

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient's age ranges from 35 to 75 years old (including 35 and 75 years old);
  • Meet the diagnostic criteria for ischemic stroke (according to the guidelines developed by the American Heart Association/American Stroke Association in 2019 and the guidelines developed by the Neurology Branch of the Chinese Medical Association in 2018) or meet the diagnostic criteria for hemorrhagic stroke (according to the guidelines developed by the American Heart Association/American Stroke Association in 2022 and the guidelines developed by the Neurology Branch of the Chinese Medical Association in 2019) ,with lesions located in the left hemisphere, and a duration of illness ranging from 15 days to 6 months.
  • Diagnosed as aphasia patient according to the Chinese version of Western Aphasia Battery (WAB), with a WAB-aphasia quotient of less than 93.8 points;
  • First onset of stroke;
  • Normal language function before the onset of stroke, and the patient's native language is Chinese with at least 6 years of education;
  • Understand the trial and signed the form.

Exclusion criteria

Exclusion Criteria:

  • Combined dysarthria (NIHSS item 10 score ≥2 points);
  • Aphasia caused by bilateral hemisphere stroke, brain tumor, traumatic brain injury, Parkinson's disease, motor neuron disease, or other diseases;
  • Patients with implanted electronic devices such as cardiac pacemakers, cochlear implants, or other metal foreign bodies, or those with MRI such as claustrophobia or TMS treatment contraindications;
  • History of epilepsy;
  • Patient with concomitant severe systemic diseases affecting the heart, lungs, liver, kidneys, etc., and uncontrolled by conventional medication, as detected and confirmed through laboratory testing and examination;
  • Patients with consciousness disorders (NIHSS 1(a) score ≥1);
  • Patients with malignant hypertension;
  • Patients with severe organic diseases, such as malignant tumors, with an expected survival time of less than 1 year;
  • Patients with severe hearing, visual, cognitive impairment or inability to cooperate with the trial;
  • Patients with severe depression, anxiety, or diagnosed with other mental illnesses that prevent them from completing the trial;
  • Patients who have received other neuromodulation treatments such as TMS, transcranial electric stimulation, etc. in the 3 months prior to enrollment;
  • Patients with a history of alcoholism, drug abuse, or other substance abuse;
  • Patients with other abnormal findings that the researchers judge are not suitable for participation in this trial;
  • Patients who are unable to complete follow-up due to geographical or other reasons;
  • Women of childbearing age who are currently pregnant, breastfeeding, or planning or may become pregnant during the trial;
  • Patients who are currently participating in other clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    active 1200-pulse cTBS group

    active 1200-pulse cTBS combined with speech language therapy

    Device: active 1200-pulse continuous Theta Burst Stimulation

  • Active comparator
    active 2400-pulse cTBS group

    active 2400-pulse cTBS combined with speech language therapy

    Device: active 2400-pulse continuous Theta Burst Stimulation

  • Active comparator
    active 3600-pulse cTBS group

    active 3600-pulse cTBS combined with speech language therapy

    Device: active 3600-pulse continuous Theta Burst Stimulation

  • Sham comparator
    sham 1200-pulse cTBS group

    sham 1200-pulse cTBS combined with speech language therapy

    Device: sham 1200-pulse continuous Theta Burst Stimulation

  • Sham comparator
    sham 2400-pulse cTBS group

    sham 2400-pulse cTBS combined with speech language therapy

    Device: sham 2400-pulse continuous Theta Burst Stimulation

  • Sham comparator
    sham 3600-pulse cTBS group

    sham 3600-pulse cTBS combined with speech language therapy

    Device: sham 3600-pulse continuous Theta Burst Stimulation

Interventions

  • Deviceactive 1200-pulse continuous Theta Burst Stimulation

    Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

  • Deviceactive 2400-pulse continuous Theta Burst Stimulation

    Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

  • Deviceactive 3600-pulse continuous Theta Burst Stimulation

    Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

  • Devicesham 1200-pulse continuous Theta Burst Stimulation

    Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

  • Devicesham 2400-pulse continuous Theta Burst Stimulation

    Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

  • Devicesham 3600-pulse continuous Theta Burst Stimulation

    Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

06

What researchers measure

Primary outcomes

  1. Change in the Western Aphasia Battery scores

    The first four subsets of the WAB (Spontaneous Speech, Auditory verbal comprehension, Repetition, Naming and word finding) will be used to evaluate the participants' language ability impairments. A Chinese adapted version of WAB will be used. The scores from all four subsets will be calculated as an Aphasia Quotient (ranging from 0 to 100), with lower Aphasia Quotients indicating poorer language abilities.

    Time frame: baseline, end of the 3-week therapy

Secondary outcomes

  1. Change in the Western Aphasia Battery scores

    The first four subsets of the WAB (Spontaneous Speech, Auditory verbal comprehension, Repetition, Naming and word finding) will be used to evaluate the participants' language ability impairments. A Chinese adapted version of WAB will be used. The scores from all four subsets will be calculated as an Aphasia Quotient (ranging from 0 to 100), with lower Aphasia Quotients indicating poorer language abilities.

    Time frame: baseline, end of the 5-day therapy, 90 days after treatment initiation

  2. Boston Diagnostic Aphasia Examination Severity Ratings

    The Boston Diagnostic Aphasia Examination (BDAE) Severity Ratings is a clinical tool used to evaluate the severity and type of aphasia in individuals. The assessment includes four domains: communication abilities, language content, speech sound production and response abilities.BDAE severity ratings range from level 0 to level 5, with lower scores indicating more severe aphasia.

    Time frame: baseline,end of the 3-week therapy,90 days after treatment initiation

  3. Chinese-version Stroke and Aphasia Quality of Life Scale 39-generic version (SAQOL-39g)

    The SAQOL-39g is a quality of life assessment tool that is used to evaluate the impact of stroke and aphasia on a patient's quality of life. It consists of 39 items that cover a range of domains related to the patient's quality of life, such as communication, physical functioning, mood, and social support. The items are rated on a 5-point Likert scale ranging from "not at all" to "very much", with higher scores indicating better quality of life.

    Time frame: baseline,end of the 3-week therapy,90 days after treatment initiation

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2025, 24 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2023
First posted
Aug 1, 2023
StartActual
Sep 22, 2023
Primary completionEst.
Sep 22, 2025
CompletionEst.
Dec 22, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05969548
Lead sponsor
Changping Laboratory
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Sep 22, 2023
Primary completion
Sep 22, 2025 (estimated)
Completion
Dec 22, 2025 (estimated)
Last update
Apr 4, 2025

Study contacts

Ruiqi Pan
Contact
ruiqipanedu@163.com
010-80726688
Hesheng Liu, PhD
study chair · Changping Laboratory

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion